TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

NHS National Transition Framework for Apremilast, Pazopanib and Dapagliflozin

No classification published
Location not published
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: NHS England: "NHS National Transition Framework for Apremilast, Pazopanib and Dapagliflozin". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityNHS EnglandScope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: NHS England
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for NHS England. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
22.8Bids / Report
7.7% of reports have one bid
Supplier ConcentrationModerate Concentration
Anna FreudTop vendor: 29.6% of attributable value
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 859 active published awards; 13 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Historical Awarded Suppliers With This Authority:
Supplier NameHistoric AwardsAttributable GBP Value
Anna Freud1 win£5,862,540
Anglia Ruskin University1 win£4,809,159
NHS Shared Business Services Limited1 win£4,393,727
Pearson Professional Assessments Limited1 win£4,374,320
Timewise Foundation CIC1 win£166,667
Procedure terms
Contracting AuthorityNHS England
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSFramework
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published30 Jan 2026, 09:48 GMT
Last source update30 Jan 2026, 09:48 GMT
Recurring procurementNot published
ClassificationNot published
Delivery areaLocation not published
OCIDocds-h6vhtk-05936a
What is being bought
Project title: NHS National Framework for Transition Products (Apremilast, Pazopanib and Dapagliflozin) commencing 1st February 2026 Offer reference number: CM/TNS/25/5735 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/25/5735 Apremilast, Pazopanib and Dapagliflozin Lot 1 DLN/DNW: 01/02/2026 to 31/01/2027 (12 months) Lot 2 DLS/DNE: 01/02/2026 to 31/01/2027 (12 months) Lot 3 DCE/DSW: 01/02/2026 to 30/09/2027 (20 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England
What changed
From the official release history
  1. Official notice release published
    30 Jan 2026, 09:48 GMT
  2. tender value changed
    26 Nov 2025, 15:36 GMT
  3. Status changed to complete
    26 Nov 2025, 15:36 GMT
  4. Official notice release published
    26 Nov 2025, 15:36 GMT
  5. Submission deadline changed to published date
    26 Nov 2025, 15:36 GMT
  6. Published value updated to £37,954,000
    2 Oct 2025, 13:32 BST
  7. Status changed to active
    2 Oct 2025, 13:32 BST
  8. Official notice release published
    2 Oct 2025, 13:32 BST
  9. Submission deadline changed to 31 Oct 2025, 13:00 GMT
    2 Oct 2025, 13:32 BST
  10. Published value updated to £35,500,000
    3 Sept 2025, 15:37 BST
  11. Status changed to planning
    3 Sept 2025, 15:37 BST
  12. Official notice release published
    3 Sept 2025, 15:37 BST
  13. Buyer information updated
    3 Sept 2025, 15:37 BST
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    complete
    Published valueNot published
    The source published no individual title or description for this lot.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    30 Jan 2026, 09:48 GMT
  2. Award active
    Not published · Not published
  3. Contract active
    Signed 5 Jan 2026, 00:00 GMT · £25,881,000
Commercial outcome and competition
Awards
Accord UK Ltd, Amarox Ltd, CELIX PHARMA LTd, DR REDDY'S LABORATORIES (UK) LIMITED, Farmak Pharmaceuticals UK Ltd, GLENMARK PHARMACEUTICALS EUROPE LIMITED, TEVA UK LIMITED, THORNTON & ROSS LIMITED, Zentiva Pharma UK Ltd
Not published · Not published · active
Contracts
Lot 1 - CM/TNS/25/5735 Apremilast, Pazopanib and Dapagliflozin
£25,881,000 · signed 5 Jan 2026, 00:00 GMT · active
Contract period: 1 Feb 2026, 00:00 GMT — 30 Sept 2027, 23:59 BST
Bid statisticsNo aggregate bid statistics published
Buyer and organisations in this procedure

NHS England

Contracting authority GB-PPON-PDPT-3135-BWWY
View buyer profile
Documents (1)
Official links; attachments are not copied

  • Not published

    tender
    conflictOfInterest
Related procedures (0)
No data
No related procedures published